EisaiEisai Glossary Eisai Glossary

 Lenvima®
 Eisai Product Names 
Novel multiple receptor tyrosine kinase inhibitor (orally administered molecular-targeted agent) discovered and developed by Eisai. Launched as a treatment for refractory thyroid cancer in the United States, Japan and Europe in 2015 and has been granted orphan drug status (a drug for rare diseases) for the treatment of thyroid cancer by the regulatory authorities in each of these regions. In 2016, indication for the treatment for renal cell carcinoma was approved in the United States and Europe.



close


Copyright (C) Eisai Co., Ltd. All Rights Reserved.